<div id="readability-page-1"><p>Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider William Jacob Savage sold 13,093 shares of the firm's stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $91.22, for a total transaction of $1,194,343.46. Following the completion of the sale, the insider owned 75,702 shares in the company, valued at $6,905,536.44. This represents a 14.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.</p><div><p><span></span><span>Get <strong>Disc Medicine</strong> alerts:</span></p></div><h2>Disc Medicine Stock Down 0.6%</h2><p>Shares of NASDAQ IRON traded down $0.53 during trading hours on Tuesday, hitting $91.47. 639,414 shares of the stock were exchanged, compared to its average volume of 536,679. Disc Medicine, Inc. has a 12 month low of $30.82 and a 12 month high of $99.50. The firm has a fifty day moving average price of $86.99 and a 200-day moving average price of $68.22. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The company has a market cap of $3.45 billion, a PE ratio of -17.10 and a beta of 0.87. </p><p>Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.29).  On average, sell-side analysts expect that  Disc Medicine, Inc. will post -4.07 EPS for the current year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several brokerages recently weighed in on IRON. Morgan Stanley boosted their target price on Disc Medicine from $90.00 to $115.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, October 30th. Stifel Nicolaus initiated coverage on Disc Medicine in a report on Monday, November 3rd. They issued a &#34;buy&#34; rating and a $125.00 price target for the company. National Bankshares  set a $153.00 price objective on shares of Disc Medicine in a report on Friday, October 17th. Cantor Fitzgerald lifted their target price on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, October 17th. Finally, Wedbush boosted their target price on shares of Disc Medicine from $90.00 to $110.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, October 17th. One investment analyst  has rated the stock with a Strong Buy rating, ten have issued  a Buy rating and one  has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $119.00.</p><p><b>Get Our Latest Stock Analysis on IRON</b></p><h2>Institutional Inflows and Outflows</h2><p>Several institutional investors have recently modified their holdings of the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of  Disc Medicine during the 3rd quarter worth approximately $38,000.  CWM LLC boosted its holdings in  Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company's stock worth $55,000 after buying an additional 711 shares in the last quarter.  Avanza Fonder AB acquired a new stake in  Disc Medicine during the second quarter valued at $57,000.  Mirae Asset Global Investments Co. Ltd. grew its position in  Disc Medicine by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company's stock valued at $71,000 after buying an additional 181 shares during the period.  Finally, Ameritas Investment Partners Inc. increased its holdings in  Disc Medicine by 8.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company's stock valued at $133,000 after buying an additional 206 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>About Disc Medicine</h2> (Get Free Report)<p>Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Disc Medicine</li><li>Utilities Stocks Explained – How and Why to Invest in Utilities</li><li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li><li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li><li>RTX Surges to Record Highs as Defense Orders Explode</li><li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li><li>Smart Money Is Buying Auto Suppliers, Not Car Brands</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Disc Medicine Right Now?</h2><p>Before you consider Disc Medicine, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.</p><p>While Disc Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IRON

<p>Disc Medicine insider William Jacob Savage sold 13,093 shares at $91.22 each, totaling $1,194,343.46. This sale reduced his position by 14.75%, leaving him with 75,702 shares valued at $6,905,536.44. The transaction was disclosed to the SEC. Disc Medicine's stock fell 0.6% to $91.47. Analysts have given the stock a "Moderate Buy" rating with a consensus price target of $119.00. Institutional investors have been adjusting their holdings in the company.</p>

Disc Medicine (NASDAQ:IRON) Insider William Jacob Savage Sells 13,093 Shares